IL142900A0 - Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer - Google Patents
Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancerInfo
- Publication number
- IL142900A0 IL142900A0 IL14290000A IL14290000A IL142900A0 IL 142900 A0 IL142900 A0 IL 142900A0 IL 14290000 A IL14290000 A IL 14290000A IL 14290000 A IL14290000 A IL 14290000A IL 142900 A0 IL142900 A0 IL 142900A0
- Authority
- IL
- Israel
- Prior art keywords
- cancer
- compositions
- treatment
- prevention
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38954599A | 1999-09-03 | 1999-09-03 | |
PCT/US2000/022806 WO2001017543A2 (en) | 1999-09-03 | 2000-08-18 | Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
IL142900A0 true IL142900A0 (en) | 2002-04-21 |
Family
ID=23538715
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14290000A IL142900A0 (en) | 1999-09-03 | 2000-08-18 | Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer |
Country Status (14)
Country | Link |
---|---|
US (1) | US20060019887A1 (xx) |
EP (2) | EP1800691A3 (xx) |
JP (2) | JP2003508491A (xx) |
KR (1) | KR20010085996A (xx) |
CN (1) | CN1345246A (xx) |
AT (1) | ATE362374T1 (xx) |
AU (1) | AU6788900A (xx) |
CA (1) | CA2349406C (xx) |
DE (1) | DE60034871T2 (xx) |
ES (1) | ES2287028T3 (xx) |
HU (1) | HUP0104688A3 (xx) |
IL (1) | IL142900A0 (xx) |
WO (1) | WO2001017543A2 (xx) |
ZA (1) | ZA200103565B (xx) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL117175A (en) | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
EP2371962A3 (en) | 1996-12-23 | 2011-12-21 | Immunex Corporation | Receptor activator of NF-KAPPA B, receptor is member of TNF receptor superfamily |
RU2238949C2 (ru) | 1997-04-15 | 2004-10-27 | Санкио Компани Лимитед | Белок, специфически связывающийся с ингибирующим остеокластогенез фактором (ocif) (варианты), днк его кодирующая (варианты), днк в качестве зонда (варианты), способ получения белка (варианты), способ скрининга вещества (варианты), антитело (варианты), способ получения поликлонального антитела, гибридома (варианты), способ получения моноклонального антитела, способ измерения ocif-связывающего белка, фармацевтическая композиция (варианты) и лекарственное средство (варианты) |
RO128635A2 (ro) | 1997-04-16 | 2013-07-30 | Amgen Inc. | Anticorp sau fragment al acestuia care se leagă la opgbp şi utilizarea acestuia, utilizarea unei forme solubile de odar, şi metodă de identificare a unui compus care descreşte activitatea opgbp |
US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
CA2328140C (en) | 1998-05-14 | 2012-03-13 | Immunex Corporation | Method of inhibiting osteoclast activity |
EP1127578A4 (en) | 1998-10-28 | 2004-12-15 | Sankyo Co | MEDICINE FOR BONE METABOLIC DEVIATIONS |
US20020090646A1 (en) * | 2000-05-03 | 2002-07-11 | Amgen Inc. | Calcitonin-related molecules |
DE01973455T1 (de) | 2000-09-22 | 2004-04-22 | Immunex Corp., Seattle | Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b |
CA2449658A1 (en) * | 2001-06-06 | 2002-12-12 | Immunex Corporation | Use of rank antagonists to treat cancer |
EP1270015A3 (en) * | 2001-06-29 | 2004-02-25 | Sankyo Company Limited | A complex comprising OCIF and Polysaccharide |
JP4761710B2 (ja) | 2002-04-05 | 2011-08-31 | アムジェン インコーポレイテッド | 選択的opgl経路インヒビターとしてのヒト抗opgl中和抗体 |
US7585840B2 (en) | 2002-04-10 | 2009-09-08 | Merck Serono S.A. | Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease |
PL372928A1 (en) | 2002-04-10 | 2005-08-08 | Applied Research Systems Ars Holding N.V. | Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease |
WO2003103709A2 (en) * | 2002-06-07 | 2003-12-18 | Trillium Therapeutics Inc. | Modulation of bone development |
NZ554390A (en) * | 2004-12-13 | 2010-07-30 | Cephalon Australia Vic Pty Ltd | Osteoprotegerin variant proteins |
TW200714289A (en) * | 2005-02-28 | 2007-04-16 | Genentech Inc | Treatment of bone disorders |
EP2442650B1 (en) * | 2009-06-12 | 2015-08-26 | Cynapsus Therapeutics Inc. | Sublingual apomorphine |
CN102242209B (zh) * | 2011-07-05 | 2013-12-11 | 北京大学人民医院 | 基于多个基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒 |
AU2012375257B2 (en) * | 2012-03-31 | 2019-09-12 | R-Pharm International, Limited Liability Company | Osteoprotegerin derived composition and use thereof |
WO2015134032A1 (en) * | 2014-03-06 | 2015-09-11 | R-Pharm Overseas, Inc. | Osteoprotegerin derived rankl inhibitor |
KR101576904B1 (ko) * | 2014-07-31 | 2015-12-14 | (주)케어젠 | 파골세포 분화 및 활성 억제능을 갖는 펩타이드 및 이의 용도 |
WO2018082758A1 (en) * | 2016-11-04 | 2018-05-11 | Aarhus Universitet | Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor |
CN110483647B (zh) * | 2019-08-19 | 2021-02-09 | 重庆大学附属肿瘤医院 | 一种抗肿瘤多肽及其应用 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4710473A (en) * | 1983-08-10 | 1987-12-01 | Amgen, Inc. | DNA plasmids |
AU610083B2 (en) * | 1986-08-18 | 1991-05-16 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents |
FR2640537B1 (fr) * | 1988-12-21 | 1992-02-21 | Levy Guy | Installation et procede utilisant l'effet laser, pour la coupe ou la vaporisation de materiaux et tissus divers |
US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
CA2082951C (en) * | 1991-03-15 | 1999-12-21 | Robert M. Platz | Pulmonary administration of granulocyte colony stimulating factor |
US5447851B1 (en) * | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
EP0615451B1 (en) * | 1992-05-26 | 2005-12-07 | Immunex Corporation | Novel cytokine that binds cd30 |
US5457035A (en) * | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
US5843901A (en) * | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
US6613544B1 (en) * | 1995-12-22 | 2003-09-02 | Amgen Inc. | Osteoprotegerin |
US6369027B1 (en) * | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
US20050147611A1 (en) * | 1995-12-22 | 2005-07-07 | Amgen Inc. | Combination therapy for conditions leading to bone loss |
US20030207827A1 (en) * | 1995-12-22 | 2003-11-06 | William J. Boyle | Osteoprotegerin |
US7005413B1 (en) * | 1995-12-22 | 2006-02-28 | Amgen Inc. | Combination therapy for conditions leading to bone loss |
-
2000
- 2000-08-18 CA CA2349406A patent/CA2349406C/en not_active Expired - Fee Related
- 2000-08-18 EP EP06022155A patent/EP1800691A3/en not_active Withdrawn
- 2000-08-18 WO PCT/US2000/022806 patent/WO2001017543A2/en active IP Right Grant
- 2000-08-18 IL IL14290000A patent/IL142900A0/xx unknown
- 2000-08-18 ES ES00955737T patent/ES2287028T3/es not_active Expired - Lifetime
- 2000-08-18 EP EP00955737A patent/EP1140136B1/en not_active Expired - Lifetime
- 2000-08-18 AT AT00955737T patent/ATE362374T1/de not_active IP Right Cessation
- 2000-08-18 HU HU0104688A patent/HUP0104688A3/hu unknown
- 2000-08-18 CN CN00802472A patent/CN1345246A/zh active Pending
- 2000-08-18 AU AU67889/00A patent/AU6788900A/en not_active Abandoned
- 2000-08-18 KR KR1020017005606A patent/KR20010085996A/ko not_active Application Discontinuation
- 2000-08-18 DE DE60034871T patent/DE60034871T2/de not_active Expired - Lifetime
- 2000-08-18 JP JP2001521333A patent/JP2003508491A/ja not_active Withdrawn
-
2001
- 2001-05-03 ZA ZA200103565A patent/ZA200103565B/en unknown
-
2004
- 2004-09-22 US US10/948,053 patent/US20060019887A1/en not_active Abandoned
-
2011
- 2011-06-01 JP JP2011123144A patent/JP2011225581A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2003508491A (ja) | 2003-03-04 |
EP1140136A2 (en) | 2001-10-10 |
EP1800691A2 (en) | 2007-06-27 |
EP1140136B1 (en) | 2007-05-16 |
CN1345246A (zh) | 2002-04-17 |
DE60034871D1 (de) | 2007-06-28 |
EP1800691A3 (en) | 2007-10-31 |
HUP0104688A2 (hu) | 2002-03-28 |
JP2011225581A (ja) | 2011-11-10 |
WO2001017543A2 (en) | 2001-03-15 |
US20060019887A1 (en) | 2006-01-26 |
ZA200103565B (en) | 2002-05-03 |
KR20010085996A (ko) | 2001-09-07 |
CA2349406C (en) | 2011-01-11 |
ES2287028T3 (es) | 2007-12-16 |
WO2001017543A3 (en) | 2001-07-26 |
ATE362374T1 (de) | 2007-06-15 |
CA2349406A1 (en) | 2001-03-15 |
DE60034871T2 (de) | 2008-01-17 |
HUP0104688A3 (en) | 2004-07-28 |
AU6788900A (en) | 2001-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL142900A0 (en) | Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer | |
IL189629A0 (en) | Compositions containing human ctla-4 antibodies | |
EP1128832A4 (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS AND RELATED DISEASES | |
ZA979961B (en) | 5-HT1F agonists | |
WO2003008583A3 (en) | Novel compositions and methods for cancer | |
MXPA03007960A (es) | Compuestos y metodos para el tratamiento de desordenes urogenitales. | |
ZA993364B (en) | Novel 4-phenylpiperidines for the treatment of pruritic dermatoses. | |
PL330496A1 (en) | Methods of and compositions for treating and preventing tumours, disorders associated with tumours as well as cachexy | |
WO2002094189A3 (en) | Compositions and methods for treating or preventing convulsions or seizures | |
WO2003045230A3 (en) | Novel compositions and methods for cancer | |
ZA200003768B (en) | Methods and compositions for treating diseases and conditions of the eye. | |
MXPA03003741A (es) | Metodos y composiciones para el tratamiento de enfermedades oftalmicas. | |
WO2003057146A3 (en) | Novel compositions and methods for cancer | |
MXPA00007394A (es) | Compuestos, composiciones y metodos para tratar o evitar infeccion de neumovirus y enfermedades asociadas. | |
EP1551388A4 (en) | COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, COMPOSITIONS AND METHODS COMPRISING THE SAME | |
WO2003053224A3 (en) | Novel compositions and methods for cancer | |
MXPA02001204A (es) | Compuestos calciliticos. | |
AU3896899A (en) | Compositions for the treatment of tumors, and uses thereof | |
IL140044A0 (en) | Compounds with growth hormone releasing properties | |
PL340459A1 (en) | Agonists of 5ht1f | |
ZA200109845B (en) | Hair treatment compositions. | |
WO2003035837A3 (en) | Novel compositions and methods for cancer | |
AU2003258176A8 (en) | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | |
MXPA05009428A (es) | Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas. | |
EP1472376A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF UROLOGICAL DISEASES USING 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318 , 2058 OR 6351 MO |